Form D · Biotechnology

Cedilla Therapeutics, Inc.

Cambridge, MA · CIK 0001824618

Offering snapshot reported Oct 25, 2021 · SEC filing

Reported sold: $82.6M
Investors reported: 24
Minimum accepted: $0
First sale: Sep 9, 2020

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$57,599,996 → $82,599,996
Reported investors19 → 24

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 25, 2021	Amendment	$82,599,996	$25,000,000vs Sep 9, 2021	24	SEC filing
Sep 9, 2021	Amendment	$57,599,996	$27,239,997vs Sep 24, 2020	19	SEC filing
Sep 24, 2020	Initial	$30,359,999	No comparison	16	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-376252

Source: Form D, filed Oct 25, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Chris Bowden	Director
Eli Casdin	Director
Abbie Celniker	Director
Neil Exter	Director
Alexandra Glucksmann	Director, Executive
Rosana Kapeller	Director
Dominik Naczynski	Director
Jake Simson	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

245 First Street
Cambridge, MA, 02142